Navigation Links
PuraMed BioScience, Inc. Has Its Lead Product, LipiGesic®M Featured in Flaherty Financial News
Date:12/28/2011

SCHOFIELD, Wis., Dec. 28, 2011 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB: PMBS) is pleased to announce that its lead product, LipiGesic®M, for the acute treatment of migraines, has been featured in the December 20, 2011 issue of Flaherty Financial News Newsletter published by Flaherty  Financial News Inc.  The report can be found at http://tinyurl.com/cf5mc6w.  

"We are very excited to be featured in the Flaherty Financial News Newsletter," said PuraMed CEO, Russ Mitchell.  "This publication has online distribution to over 10 million investors and we think this is a great step in getting the word out about our product, LipiGesic®M." 

About Flaherty Financial News Inc.
Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of the neglected micro-and small-cap markets. It was launched in February 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., together with his son Brian, who serves as President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years until it was sold in September 2006, Bob was also Editor-in-Chief of Equities Special Situations, which had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. Previously, he was an award-winning Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School.

About the PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products.  PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study.  http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract.  LipiGesic®M has national distribution and is available nationwide in some of the largest chain drug stores in the United States.  In addition to LipiGesic®M, the Company also has plans to launch LipiGesic®H for tension-type headaches as well as LipiGesic®PM which provides a remedy for insomnia and other sleep disorders.

Forward-Looking Statements:  
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com

Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy
847-945-2222
www.investorawareness.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Crown Bioscience, Inc. Announces Closing of Series C Financing
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
3. FDA Tentatively Approves Intellijects Lead Product, e-cue™
4. PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184
5. Equinox Surgical Solutions Launches Flagship Product, SutureAssist®
6. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
7. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
8. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
9. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
10. Nonin Medical GO2™ Finger Pulse Oximeter to be Featured on "The Balancing Act" TV Show on Lifetime Television
11. ClinStar to Be Featured on Business Day TV With Terry Bradshaw
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... The IPF pipeline is very strong with a total of 97 ... Inc., Biogen and Sanofi are involved in the development of the IPF ... is in Phase III stage, 15 are in Phase II stage, 12 ...
(Date:3/24/2017)... March 24, 2017 A ReportsnReports.com report says, ... growing rapidly as the global sales of Adcetris and Kadcyla have ... the antibody drug conjugates market is driven by large number of ... wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... In just two ... Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so ... nearly 2,000 consumers (and counting) already backing the campaign. , “We are ...
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy ... societal issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... for causes around the world. , Running for charity has become a ...
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National Council on ... The NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at ... in the U.S. It argues that this higher bar should be set by states, ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is revolutionizing ... a huge impact on businesses and individual consumers alike. Laboratories can maximize their ... a value anywhere from $4 trillion to $11 trillion dollars by the year 2025. ...
Breaking Medicine News(10 mins):